Renal Denervation for Management of Drug-Resistant Hypertension (INSPiRED)
Primary Purpose
Hypertension
Status
Completed
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
Renal denervation
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Treatment-resistant hypertension, Renal denervation, Sympathetic nervous system
Eligibility Criteria
Inclusion criteria:
- Women and men are eligible. Women of reproductive age should apply effective contraception.
- Age ranges from 20 years (inclusive) to less than 70 years.
- Patients should have essential hypertension.
- Treatment-resistant hypertension in patients taking a stable drug regimen for at least 4 weeks consisting of 3 or more antihypertensive medications from different classes, including a diuretic.
- Under maximal therapy, office blood pressure should be ≥140/90 mmHg and the 24-h ambulatory blood pressure should be 130 mm Hg systolic or 80 mm Hg diastolic or higher.
- eGFR must be ≥ 60 mL/min/1.73 m2.
- The patients should accept to have adherence checked before randomisation and during supervised follow-up, but both patients and doctors will remain blinded to the results;
- Informed written consent.
Exclusion criteria:
- Suboptimal clinical context, because of recent history or concurrent disease.
- Isolated systolic and diastolic hypertension.
- Body-mass index ≥ 40kg/m2.
- The anatomy of the renal arteries is suboptimal for renal denervation.
- Pregnancy.
- Alcohol or substance abuse or psychiatric illnesses.
- Participation in other study.
- The clinical context is suboptimal for renal denervation.
Sites / Locations
- Cliniques Universitaires Saint-Luc
- Universitair Ziekenhuis Gasthuisberg
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Experimental
Arm Label
Control group
Intervention group
Arm Description
Standard antihypertensive drug treatment
Renal denervation plus standard antihypertensive drug treatment
Outcomes
Primary Outcome Measures
Change in Systolic Blood Pressure From Baseline to 6 Months on 24-h Ambulatory Measurement (Follow-up Minus Baseline Measurement)
The primary endpoint deals with efficacy of renal denervation with regard to controlling blood pressure on ambulatory measurement. It consists of the baseline-adjusted between-group difference in the changes in 24-h systolic blood pressure. Because automated blood pressure monitors will be used, the assessment of the primary endpoint is blind.
Change in Glomerular Filtration Rate
The primary endpoint for safety of renal denervation is the baseline-adjusted between group difference in the change of glomerular filtration rate estimated by using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation.
Secondary Outcome Measures
The Intensity of Medical Treatment
The number and doses of blood-pressure lowering drugs in the 2 arms of the trial.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01505010
Brief Title
Renal Denervation for Management of Drug-Resistant Hypertension
Acronym
INSPiRED
Official Title
Investigator-Steered Project on Intravascular Renal Denervation for Management of Drug-Resistant Hypertension
Study Type
Interventional
2. Study Status
Record Verification Date
March 2020
Overall Recruitment Status
Completed
Study Start Date
April 2014 (Actual)
Primary Completion Date
December 31, 2016 (Actual)
Study Completion Date
March 31, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
KU Leuven
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
INSPiRED is a multicenter parallel-group trial comparing usual medical treatment (control group) or usual medical treatment plus renal denervation (intervention). In both groups adherence will be monitored both before randomization and during 36 months of follow-up.
Detailed Description
Objectives:
To compare the blood pressure lowering efficacy and safety of renal denervation vs. usual medical therapy. The primary endpoints for efficacy and safety are the baseline-adjusted between-group differences in 24-h systolic blood pressure and in glomerular filtration rate as estimated by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. Secondary endpoints for efficacy and safety include other indexes of blood pressure control and renal function, metabolic variables and morbidity and mortality. These endpoints will be assessed 6 months after randomization.
Trial design:
Randomized controlled trial with blinded assessment of the primary and secondary endpoints. The study consists of 6 stages. Supervised and nonsupervised follow-up refer to assessment of outcome at or outside the participating center, respectively.
Screening involves checking eligibility and ruling out secondary hypertension.
Run-in period of 3 months to optimize medical treatment and to assess adherence to treatment.
Stratification and randomization Eligible patients will be stratified by center and age group (adults vs. elderly, 20-49 vs. 50-69 years) and randomized centrally in a one-to-one proportion to control or intervention.
Renal sympathetic denervation in the intervention group, patients of the control group will be offered renal denervation after 6 months.
Supervised follow-up at 1, 3 and 6 months after randomization.
Long-term supervised or non-supervised follow-up of morbidity and mortality beyond 6 months and up to 3 years.
Sample size:
To detect a 10-mm Hg difference (SD 20 mm Hg) in systolic blood pressure between the randomized groups with a 2-sided P-value of 0.01 and 90% power in total 240 patients need to be randomized. Allowing 50% screening failures, 480 patients would have to be screened.
Assessment of adherence:
Adherence to treatment will be assessed by measurement of drugs or drug metabolites in biological fluids. Jung and coworkers developed a liquid chromatography-mass spectrometric method that allows detecting all antihypertensive drugs or their metabolites in a single urine sample. This obligatory approach will be implemented.
Assessment of quality of life Assessment of quality of life is compulsory at baseline and at each visit during the supervised follow-up, using the EuroQol 5D.
Assessment of sympathetic modulation:
heart rate variability (HRV) will be assessed at baseline and at the 6-month follow-up visit, based on 15 minutes ECG recordings. A software program, developed in LabVIEW by the group of Aubert et al. will be used.
Relevance:
INSPiRED differs from previous and ongoing studies in several aspects: (1) a stringent selection of patients; (2) drug optimization with assessment of adherence throughout the study; (3) out-of-the-office blood pressure for patient selection and follow-up; (4) state-of-the-art renal artery imaging by computerized tomographic angiography; (5) validation of urinary proteomic biomarkers to predict blood pressure responses and changes in renal function; (6) follow-up will be beyond 6 months up to 3 years; (7) use of heart rate variability and renal nerve stimulation to assess the completeness of renal denervation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Treatment-resistant hypertension, Renal denervation, Sympathetic nervous system
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Parallel group trial
Masking
None (Open Label)
Allocation
Randomized
Enrollment
17 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Control group
Arm Type
Other
Arm Description
Standard antihypertensive drug treatment
Arm Title
Intervention group
Arm Type
Experimental
Arm Description
Renal denervation plus standard antihypertensive drug treatment
Intervention Type
Procedure
Intervention Name(s)
Renal denervation
Other Intervention Name(s)
Renal denervation, using an intravascular catheter system
Intervention Description
Renal denervation in the intervention group
Primary Outcome Measure Information:
Title
Change in Systolic Blood Pressure From Baseline to 6 Months on 24-h Ambulatory Measurement (Follow-up Minus Baseline Measurement)
Description
The primary endpoint deals with efficacy of renal denervation with regard to controlling blood pressure on ambulatory measurement. It consists of the baseline-adjusted between-group difference in the changes in 24-h systolic blood pressure. Because automated blood pressure monitors will be used, the assessment of the primary endpoint is blind.
Time Frame
The primary endpoint has been assessed 6 months after randomization.
Title
Change in Glomerular Filtration Rate
Description
The primary endpoint for safety of renal denervation is the baseline-adjusted between group difference in the change of glomerular filtration rate estimated by using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation.
Time Frame
This endpoint has been assessed 6 months after randomization.
Secondary Outcome Measure Information:
Title
The Intensity of Medical Treatment
Description
The number and doses of blood-pressure lowering drugs in the 2 arms of the trial.
Time Frame
This endpoint will be assessed 6 months after randomization.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
69 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria:
Women and men are eligible. Women of reproductive age should apply effective contraception.
Age ranges from 20 years (inclusive) to less than 70 years.
Patients should have essential hypertension.
Treatment-resistant hypertension in patients taking a stable drug regimen for at least 4 weeks consisting of 3 or more antihypertensive medications from different classes, including a diuretic.
Under maximal therapy, office blood pressure should be ≥140/90 mmHg and the 24-h ambulatory blood pressure should be 130 mm Hg systolic or 80 mm Hg diastolic or higher.
eGFR must be ≥ 60 mL/min/1.73 m2.
The patients should accept to have adherence checked before randomisation and during supervised follow-up, but both patients and doctors will remain blinded to the results;
Informed written consent.
Exclusion criteria:
Suboptimal clinical context, because of recent history or concurrent disease.
Isolated systolic and diastolic hypertension.
Body-mass index ≥ 40kg/m2.
The anatomy of the renal arteries is suboptimal for renal denervation.
Pregnancy.
Alcohol or substance abuse or psychiatric illnesses.
Participation in other study.
The clinical context is suboptimal for renal denervation.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jan A. Staessen, MD, PhD
Organizational Affiliation
University of Leuven
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cliniques Universitaires Saint-Luc
City
Brussels
ZIP/Postal Code
BE-1200
Country
Belgium
Facility Name
Universitair Ziekenhuis Gasthuisberg
City
Leuven
ZIP/Postal Code
BE-3000
Country
Belgium
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Anonymized data can be made available via a motivated data transfer request (for scientific purposes only) via the PI (Prof Jan A. Staessen) and pending ethics approval.
IPD Sharing Time Frame
Currently available until 2025
IPD Sharing Access Criteria
Ethics approval
Citations:
PubMed Identifier
28489464
Citation
Jacobs L, Persu A, Huang QF, Lengele JP, Thijs L, Hammer F, Yang WY, Zhang ZY, Renkin J, Sinnaeve P, Wei FF, Pasquet A, Fadl Elmula FEM, Carlier M, Elvan A, Wunder C, Kjeldsen SE, Toennes SW, Janssens S, Verhamme P, Staessen JA; European Network Coordinating Research on Renal Denervation. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Press. 2017 Dec;26(6):321-331. doi: 10.1080/08037051.2017.1320939. Epub 2017 May 10.
Results Reference
result
PubMed Identifier
24742341
Citation
Jin Y, Jacobs L, Baelen M, Thijs L, Renkin J, Hammer F, Kefer J, Petit T, Verhamme P, Janssens S, Sinnaeve P, Lengele JP, Persu A, Staessen JA; investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) investigators. Rationale and design of the Investigator-Steered Project on Intravascular Renal Denervation for Management of Drug-Resistant Hypertension (INSPiRED) trial. Blood Press. 2014 Jun;23(3):138-46. doi: 10.3109/08037051.2014.899297. Epub 2014 Apr 17.
Results Reference
derived
Learn more about this trial
Renal Denervation for Management of Drug-Resistant Hypertension
We'll reach out to this number within 24 hrs